55052-26-1

Usage

Uses

Used in Pharmaceutical Industry:
6H-Pyrrolo[2,3-b]pyridin-6-one, 1,7-dihydrois utilized as a building block for the synthesis of various bioactive molecules and drugs. Its distinctive structure and reactivity make it a valuable component in the creation of new pharmaceuticals, contributing to the development of innovative treatments and therapies.
Used in Materials Science:
Beyond its pharmaceutical applications, 6H-Pyrrolo[2,3-b]pyridin-6-one, 1,7-dihydroalso holds potential in the field of materials science. Its unique properties may be leveraged to develop new materials with specific characteristics for various applications.
Used as a Research Tool in Chemical Biology:
6H-Pyrrolo[2,3-b]pyridin-6-one, 1,7-dihydroserves as a research tool in chemical biology, aiding scientists in understanding complex biological processes and interactions at the molecular level. Its use in research can lead to advancements in both fundamental biological science and the discovery of new therapeutic agents.

InChI:InChI=1/C7H6N2O/c10-6-2-1-5-3-4-8-7(5)9-6/h1-4H,(H2,8,9,10)

Upstream product

• 111293-49-3 6-acetoxy-1-acetyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine 
• 55052-25-0 1-acetyl-1H-pyrrolo[2,3-b]pyridin-6-yl acetate 
• 99068-42-5 2,3-dihydro-pyrrolo[2,3-b]pyridine-1-carboxylic acid ethyl ester 
• 114402-41-4 2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-7-oxide 
• 10592-27-5 7-azaindoline 

Downstream Products

• 896722-53-5 6-methoxy-1H-pyrrolo[2,3-b]pyridine 

Relevant academic research and scientific papers

AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS

Provided herein are compounds of Formula (I) and Formula (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of tuberculosis.

MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES

The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Scaffold-hopping strategy: Synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents

Utilizing scaffold-hopping drug-design strategy, we sought to identify a backup drug candidate for BPR0L075 (1), an indole-based anticancer agent. For this purpose, 5,6-fused bicyclic heteroaromatic scaffolds were designed and synthesized through shufflin

Anti-tumor compounds

Compounds of the following formula: wherein A, D, Q, T, U, V, W, X, Y, Z, R1, and ---- are as defined herein. This invention also relates to a method of inhibiting tubulin polymerization, or treating cancer or an angiogenesis-related disorder w